Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer's disease and related dementias in a multi-site autopsy cohort
Brenna CholertoniD, Dana GodrichiD, Jeremy PasterisiD, Joe Rivero, Eden R. MartiniD, Brian W. KunkleiD, Adam Christian NajiD, Kara L. Hamilton‐NelsoniD, Hui WangiD, Wan-Ping Lee, Logan C. DumitrescuiD, Timothy J. HohmaniD, Richard P MayeuxiD, Eric Berg LarsoniD, Paul K. CraneiD, Christopher Dirk KeeneiD, Caitlin S. LatimeriD, Shubhabrata MukherjeeiD, Julia K. Kofler, M. Ilyas KambohiD, David A. A BennettiD, Laura Molina‐PorceliD, Michael L. CuccaroiD, Margaret Ann Pericak‐VanceiD, Tatjana RundekiD, , Thomas Jude MontineiD
Abstract
Understanding the genetic foundations of dementia is critical to unraveling its complex molecular basis. Given that a clinical diagnosis of Alzheimers disease (AD) dementia often results from interplay between multiple underlying neuropathologic co-morbidities, previous genome-wide association studies (GWAS) of clinically diagnosed AD are restricted in their ability to translate genetic associations to potential targeted therapeutics. The current study seeks to address these limitations by presenting the largest GWAS to date (n=12,509) of neuropathologic hallmarks of AD and AD related dementias (ADRDs). We further performed a candidate-variant analysis using loci previously identified in GWAS of clinically diagnosed AD dementia and Parkinsons disease (PD). Finally, we conducted heritability and genetic correlation analyses using linkage disequilibrium (LD) score regression. We found broad genome-wide significant associations with APOE across AD and ADRDs but not cerebrovascular disease and vascular brain injury. We further identified 12 significant loci across 10 neuropathologic phenotypes, including 5 loci previously implicated in GWAS of clinical AD and ADRDs (variants on BIN1, PICALM / EED, TMEM106B, GRN, and SNCA / SNCA-AS1) and 7 novel genome-wide associations (variants on EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4 and SLAIN2 / SLC10A4). Our analysis of AD and PD clinical candidate variants demonstrated several that were associated with AD neuropathologic change and Lewy body disease, as well as substantial overlap with neuropathologic lesions other than the primary neuropathologic hallmarks of these diseases. Heritability analyses demonstrated heritability that was high for amyloid plaques (78%) relative to prior clinical AD heritability analyses, intermediate for TDP-43 inclusions (41%), and low for remaining AD and ADRD pathologic features. This study underscores the importance of investigating the underlying neuropathologic hallmarks of AD and ADRDs as a step toward refining the translation of genetic associations to biomarker interpretation and development of targeted therapeutics. Author SummaryClinically diagnosed Alzheimers disease (AD) dementia is commonly associated with its hallmark pathologic changes plus neuropathologic features of prevalent co-morbid diseases such as cerebrovascular disease, Lewy body disease, and more recently discovered abnormalities in protein called TDP-43 (collectively, AD related dementias; ADRD). As a result, previous studies that associated clinical diagnosis of AD with specific genes may not tell us the whole story. For this study, we gathered autopsy and genetic data to identify relationships between genes and dementia-associated brain changes. We found some relationships between these diseases and genes that had been previously identified as contributing to clinical dementia, as well as some new relationships that had been previously unknown. We also found that some genes that had previously been identified in relation to AD were associated with different dementia-associated brain lesions. Finally, we found that the various brain lesions differ in the proportion that can be attributed to genetic vs. environmental differences. These results support that the pathway to a diagnosis of dementia can be caused by multiple factors and are an important step in beginning to identify individually based dementia treatments.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 1.05
- Field percentile
- top 22%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic Associations with Alzheimer's, Lewy Body and Vascular Neuropathology Reveal Shared and Distinct Biological Pathways
Kevin Morgan, Alan J. Thomas, Keeley J. Brookes·medRxiv·Sep 22, 2026
- Genetic meta-analysis identifies 9 novel loci and functional pathways for Alzheimers disease risk
Iris E. Jansen, Jeanne E. Savage, … Daniëlle Posthuma·bioRxiv·Feb 22, 2018
- Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer disease and three causality networks of AD: the GR@ACE project.
Sonia Moreno–Grau, Itziar de Rojas, … Mario Carrión‐Claro·Alzheimer s & DementiaPeer-reviewed·Aug 28, 2019
- Neuropathology-based GWAS for Alzheimer's disease reveals novel susceptibility loci and highlights sex-specific pathways
Yin Hua Jin, Apostolia Topaloudi, … Peristera Paschou·medRxiv·Dec 17, 2023
- Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing
B K Kunkle, Benjamin Grenier‐Boley, … Clive Holmes·bioRxiv·Apr 5, 2018
- Multivariate Modeling of Direct and Proxy GWAS Indicates Substantial Common Variant Heritability of Alzheimer's Disease
Javier de la Fuente, Andrew David Grotzinger, … Elliot M. Tucker–Drob·medRxiv·May 6, 2021